Pneumococcal disease: cases caused by serotypes not in Prevenar 13 vaccine
Updated 8 July 2025
Applies to England
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/pneumococcal-disease-caused-by-strains-not-covered-by-prevenar-13-vaccine/pneumococcal-disease-infections-caused-by-serotypes-not-in-prevenar-13-vaccine
The number of invasive pneumococcal disease (IPD) cases due to any serotype not covered by Prevenar13™ had been increasing year on year before the COVID-19 pandemic.
In the 2020 to 2021 epidemiological year cumulative case numbers were at their lowest since 2006 in all age groups because of pandemic restrictions.
Cumulative weekly case numbers in 2024 to 2025 up to week 20 were similar to the 2023 to 2024 epidemiological year in the under 2 and 2 to 4 years age groups. The cumulative weekly case numbers in the 5 to 64 years and 65 years and above age groups were higher compared to 2023 to 2024.
Not PCV13 less than 2 years
Figure 1. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes not covered in Prevenar13™: children aged under 2 years in England by epidemiological year July to June (2017/2018 to 2024/2025 to date)
For comparison purposes, 58, 79 and 126 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
Not PCV13 2 to 4 years
Figure 2. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes not in Prevenar13™: children aged 2 to 4 years in England by epidemiological year July to June (2017/2018 to 2024/2025 to date)
For comparison purposes, 12, 29 and 63 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
Not PCV13 5 to 64 years
Figure 3. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes in not covered in Prevenar13™: persons aged 5 to 64 years in England by epidemiological year July to June (2017/2018 to 2024/2025 to date)
For comparison purposes, 496, 843 and 1,081 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
Not PCV13 over 65 years
Figure 4. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes not covered in Prevenar13™: persons aged 65 years and over in England by epidemiological year July to June (2017/2018 to 2024/2025 to date)
For comparison purposes, 466, 966 and 1,394 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
The above graphs are based on week of isolation, therefore numbers for the most recent weeks may not be complete. Numbers of reports of serotyped cases shown in the graph are not adjusted to account for any change that may have occurred over time and between age groups in the proportion of all IPD cases that are serotyped.
The 7-valent pneumococcal conjugate vaccine (Prevenar 7) was introduced into the childhood immunisation schedule on 4 September 2006.
The 13-valent pneumococcal conjugate vaccine (Prevenar 13) was introduced into the childhood immunisation schedule on 1 April 2010.
The vaccine schedule for this vaccine changed for infants born on or after January 2020 (with doses given at 12 weeks and 1 year of age (1+1) instead of 8 weeks, 16 weeks and 1 year of age (2+1)).
Source
Immunisation and Vaccine Preventable Diseases Division, UKHSA (formerly Public Health England).